{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:39:33Z","timestamp":1792528773401,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05956-9","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T05:51:15Z","timestamp":1792475475000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-inflammatory versus metabolic therapy in MASLD: a randomized clinical trial of aspirin and dapagliflozin using fibroscan outcomes"],"prefix":"10.1007","author":[{"given":"Eman Mostafa","family":"Hamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reham A.","family":"Al-Dhelaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad T.","family":"Alsulami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Khallaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed S.","family":"Badran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya Anwar Mustafa","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"5956_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-28078-3","volume":"16","author":"FT Alsulami","year":"2026","unstructured":"Alsulami FT, Hamed EM (2026) Early initiation of low-dose aspirin for the prevention of pre-eclampsia in high-risk pregnancies. Sci Rep 16:1761. https:\/\/doi.org\/10.1038\/s41598-025-28078-3","journal-title":"Sci Rep"},{"key":"5956_CR2","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1002\/hep.29363","volume":"66","author":"S Augustin","year":"2017","unstructured":"Augustin S, Pons M, Maurice JB et al (2017) Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. Hepatology 66:1980\u20131988. https:\/\/doi.org\/10.1002\/hep.29363","journal-title":"Hepatology"},{"key":"5956_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/09537104.2021.1883574","volume":"33","author":"P Czajka","year":"2022","unstructured":"Czajka P, Przyby\u0142kowski A, Nowak A et al (2022) Antiplatelet drugs and liver fibrosis. Platelets 33:219\u2013228. https:\/\/doi.org\/10.1080\/09537104.2021.1883574","journal-title":"Platelets"},{"key":"5956_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106730","volume":"86","author":"MK ElMahdy","year":"2020","unstructured":"ElMahdy MK, Helal MG, Ebrahim TM (2020) Potential anti-inflammatory effect of dapagliflozin in HCHF diet-induced fatty liver degeneration through inhibition of TNF-\u03b1, IL-1\u03b2, and IL-18 in rat liver. Int Immunopharmacol 86:106730. https:\/\/doi.org\/10.1016\/j.intimp.2020.106730","journal-title":"Int Immunopharmacol"},{"key":"5956_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK et al (2020) A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 73:202\u2013209. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039","journal-title":"J Hepatol"},{"key":"5956_CR6","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity (2024) EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 81:492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"5956_CR7","doi-asserted-by":"publisher","first-page":"7806860","DOI":"10.1155\/2020\/7806860","volume":"2020","author":"YM Han","year":"2020","unstructured":"Han YM, Lee YJ, Jang YN et al (2020) Aspirin improves nonalcoholic fatty liver disease and atherosclerosis through regulation of the PPAR\u03b4-AMPK-PGC-1\u03b1 pathway in dyslipidemic conditions. Biomed Res Int 2020:7806860. https:\/\/doi.org\/10.1155\/2020\/7806860","journal-title":"Biomed Res Int"},{"key":"5956_CR8","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK et al (2018) Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease (E-LIFT Trial). Diabetes Care 41:1801\u20131808. https:\/\/doi.org\/10.2337\/dc18-0165","journal-title":"Diabetes Care"},{"key":"5956_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.14218\/JCTH.2019.00051","volume":"8","author":"R Kumar","year":"2020","unstructured":"Kumar R, Priyadarshi RN, Anand U (2020) Non-alcoholic fatty liver disease: growing burden, adverse outcomes and associations. J Clin Transl Hepatol 8:76\u201386. https:\/\/doi.org\/10.14218\/JCTH.2019.00051","journal-title":"J Clin Transl Hepatol"},{"key":"5956_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s13300-017-0355-3","volume":"9","author":"PCH Lee","year":"2018","unstructured":"Lee PCH, Gu Y, Yeung MY et al (2018) Dapagliflozin and empagliflozin ameliorate hepatic dysfunction among Chinese subjects with diabetes in part through glycemic improvement: a single-center, retrospective, observational study. Diabetes Ther 9:285\u2013295. https:\/\/doi.org\/10.1007\/s13300-017-0355-3","journal-title":"Diabetes Ther"},{"key":"5956_CR11","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41591-019-0379-5","volume":"25","author":"M Malehmir","year":"2019","unstructured":"Malehmir M, Pfister D, Gallage S et al (2019) Platelet GPIb\u03b1 is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat Med 25:641\u2013655. https:\/\/doi.org\/10.1038\/s41591-019-0379-5","journal-title":"Nat Med"},{"key":"5956_CR12","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1111\/jgh.15580","volume":"36","author":"S Phrueksotsai","year":"2021","unstructured":"Phrueksotsai S, Pinyopornpanish K, Euathrongchit J et al (2021) The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 36:2952\u20132959. https:\/\/doi.org\/10.1111\/jgh.15580","journal-title":"J Gastroenterol Hepatol"},{"key":"5956_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-00980-1","volume":"22","author":"S Pouwels","year":"2022","unstructured":"Pouwels S, Sakran N, Graham Y et al (2022) Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord 22:63. https:\/\/doi.org\/10.1186\/s12902-022-00980-1","journal-title":"BMC Endocr Disord"},{"key":"5956_CR14","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS et al (2023) AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77:1797\u20131835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323","journal-title":"Hepatology"},{"key":"5956_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108610","volume":"37","author":"M Shi","year":"2023","unstructured":"Shi M, Zhang H, Wang W et al (2023) Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease. J Diabetes Complicat 37:108610. https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108610","journal-title":"J Diabetes Complicat"},{"key":"5956_CR16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/dom.13520","volume":"21","author":"M Shimizu","year":"2019","unstructured":"Shimizu M, Suzuki K, Kato K et al (2019) Evaluation of the effects of dapagliflozin on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab 21:285\u2013292. https:\/\/doi.org\/10.1111\/dom.13520","journal-title":"Diabetes Obes Metab"},{"key":"5956_CR17","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1016\/j.cgh.2019.04.061","volume":"17","author":"TG Simon","year":"2019","unstructured":"Simon TG, Henson J, Osganian S, Masia R, Chan AT, Chung RT, Corey KE (2019) Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 17:2776-2784.e4. https:\/\/doi.org\/10.1016\/j.cgh.2019.04.061","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5956_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X","journal-title":"Lancet"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05956-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05956-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05956-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:02:52Z","timestamp":1792526572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05956-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":18,"alternative-id":["5956"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05956-9","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present study was approved by the Ethical Committee of the Faculty of Medicine, Beni-Suef University (approval number FMBSUREC\/04032025). The study was conducted in accordance with the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants for both their involvement in the study and the anonymous use of their data for publication.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}